title: Dual PI3K/mTOR inhibitors: does p53 modulate response?
abstract: Head and neck squamous cell carcinomas have multiple genetic alterations that can influence clinical response to treatment. It is important to evaluate how distinct alterations affect response to targeted agents to identify a subset of patients who can benefit from therapy, improving survival and decreasing toxicity.
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery and Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, Louisiana 71130, USA.
authors.forename: Oleksandr
authors.initials: O
authors.lastname: Ekshyyan
authors.forename: Arunkumar
authors.initials: A
authors.lastname: Anandharaj
authors.forename: Cherie-Ann O
authors.initials: CA
authors.lastname: Nathan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D011728:Pyridones / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C570662:2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one; D000970:Antineoplastic Agents; D011728:Pyridones; D011743:Pyrimidines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53